Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Fox Run Management L.L.C.

Fox Run Management L.L.C. cut its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 6.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 52,342 shares of the biotechnology company’s stock after selling 3,684 shares during the quarter. Fox Run Management L.L.C.’s holdings in Arrowhead Pharmaceuticals were worth $984,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. State Street Corp lifted its stake in shares of Arrowhead Pharmaceuticals by 8.8% during the third quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company’s stock valued at $123,083,000 after buying an additional 516,569 shares during the period. Edgestream Partners L.P. purchased a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $2,264,000. Fisher Asset Management LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 941.0% during the third quarter. Fisher Asset Management LLC now owns 122,260 shares of the biotechnology company’s stock valued at $2,368,000 after buying an additional 110,516 shares during the period. Wealthfront Advisers LLC purchased a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $2,060,000. Finally, King Luther Capital Management Corp purchased a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $1,447,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ARWR has been the topic of several recent analyst reports. Sanford C. Bernstein reduced their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a research note on Friday, November 29th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. Citigroup cut their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 27th. B. Riley reaffirmed a “buy” rating and set a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. Finally, StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $41.44.

Insider Activity at Arrowhead Pharmaceuticals

In related news, COO Patrick O’brien sold 29,184 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $19.82, for a total transaction of $578,426.88. Following the completion of the sale, the chief operating officer now directly owns 535,201 shares of the company’s stock, valued at approximately $10,607,683.82. This trade represents a 5.17 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider James C. Hamilton sold 32,729 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $19.82, for a total transaction of $648,688.78. Following the sale, the insider now directly owns 272,122 shares of the company’s stock, valued at approximately $5,393,458.04. The trade was a 10.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 301,730 shares of company stock valued at $5,352,844. Corporate insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR stock opened at $14.80 on Friday. The company’s fifty day simple moving average is $18.58 and its 200-day simple moving average is $19.90. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $14.23 and a 52 week high of $30.41. The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27. The company has a market cap of $2.03 billion, a PE ratio of -2.86 and a beta of 0.92.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). As a group, equities research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.